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Objectives:We recently demonstrated in a murine model that nanoparticle-mediated delivery of pitavastatin into vascular
endothelial cells effectively increased therapeutic neovascularization. For the development of a clinically applicable
approach, further investigations are necessary to assess whether this novel system can induce the development of collateral
arteries (arteriogenesis) in a chronic ischemia setting in larger animals.
Methods: Chronic hind limb ischemia was induced in rabbits. They were administered single injections of nanoparticles
loaded with pitavastatin (0.05, 0.15, and 0.5 mg/kg) into ischemic muscle.
Results: Treatment with pitavastatin nanoparticles (0.5 mg/kg), but not other nanoparticles, induced angiographically visible
arteriogenesis. The effects of intramuscular injections of phosphate-buffered saline, fluorescein isothiocyanate (FITC)-loaded
nanoparticles, pitavastatin (0.5 mg/kg), or pitavastatin (0.5 mg/kg) nanoparticles were examined. FITC nanoparticles were
detected mainly in endothelial cells of the ischemic muscles for up to 4 weeks. Treatment with pitavastatin nanoparticles, but not
other treatments, induced therapeutic arteriogenesis and ameliorated exercise-induced ischemia, suggesting the development of
functional collateral arteries. Pretreatment with nanoparticles loaded with vatalanib, a vascular endothelial growth factor receptor
(VEGF) tyrosine kinase inhibitor, abrogated the therapeutic effects of pitavastatin nanoparticles. Separate experiments with mice
deficient for VEGF receptor tyrosine kinase demonstrated a crucial role of VEGF receptor signals in the therapeutic angiogenic
effects.
Conclusions:The nanotechnology platform assessed in this study (nanoparticle-mediated endothelial cell-selective delivery
of pitavastatin) may be developed as a clinically feasible and promising strategy for therapeutic arteriogenesis in patients.
( J Vasc Surg 2010;52:412-20.)
Clinical Relevance: Restoration of tissue perfusion in patients with critical limb ischemia is a major therapeutic goal.
Recent clinical trials designed to induce neovascularization by administering exogenous angiogenic growth factors or cells
failed to demonstrate a decisive clinical benefit. A controlled drug delivery system for a new approach to therapeutic
neovascularization therefore would be more favorable. In the present study, we applied nanoparticle-mediated delivery
system and report that endothelial cell-selective delivery of pitavastatin increased the development of collateral arteries
and improved exercise-induced ischemia in a rabbit model of chronic hind limb ischemia. This nanotechnology platform
is a promising strategy for the treatment of patients with severe organ ischemia and represents a significant advance in
therapeutic arteriogenesis over current approaches.The vascular endothelium is a major target for the
pleiotropic (nonlipid-related) vascular protective effects of
the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
(statins).1 Statins improve endothelial dysfunction1-3 and
exert multiple vascular protective properties, mainly by
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412enhancing the activity of endothelial nitric oxide synthase.
Statins increase the angiogenic activity of mature endothe-
lial cells, as well as that of endothelial progenitor cells, and
augment neovascularization (arteriogenesis, vasculogen-
esis, and angiogenesis) in the ischemic hearts and limbs of
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Volume 52, Number 2 Oda et al 413experimental animals.4-6 Statins also attenuate atheroscle-
rosis formation7 and pose little potential risk for tumor
angiogenesis, in contrast to angiogenic growth factors.8
Most of these beneficial effects of statins on therapeutic
neovascularization, however, were observed after the daily
administration of high doses in experimental animals, a
regimen that could lead to serious adverse side effects in a
clinical setting. A clinical study of 500 patients with coro-
nary artery disease reported no effects of statins within the
clinical dose range on indices of functional collateral devel-
opment (arteriogenesis).9
To optimize the therapeutic effects of statins in the
induction of therapeutic neovascularization, we recently
applied nanotechnology and reported that nanoparticle
(NP)-mediated pitavastatin delivery into vascular endothe-
lial cells effectively increased therapeutic neovascularization
with no serious side effects in a murine model of acute hind
limb ischemia.10 The beneficial effects induced by pitavastatin-
NP were mediated by increased activity of endothelial nitric
oxide synthase (eNOS) and multiple endogenous angio-
genic growth factors, suggesting that this NP-mediated
cell-selective delivery produces a well-harmonized integra-
tive system for therapeutic neovascularization. Impor-
tantly, this NP-mediated delivery system was as effective at
a dose that is approximately 100 to 300 times lower than
the cumulative systemic dose. To translate our experimen-
tal findings in the murine model of acute hind limb isch-
emia to clinically applicable approaches, it is desirable to
determine whether NP-mediated statin delivery into vascu-
lar endothelial cells induces the development of collateral
arteries (arteriogenesis) and thus restores tissue perfusion in
a setting of chronic ischemia in larger animals.
Recent evidence suggests that arteriogenesis is a very
important adaptive mechanism for the restoration of perfu-
sion to critically ischemic tissue.11 Arteriogenesis is the
process whereby a preexisting arteriole from the resistance
vessel class matures into an artery of the conductance vessel
class, whereas angiogenesis is the process by which a sprout-
ing capillary originates from a preexisting capillary. Vascu-
logenesis represents the differentiation of bone marrow-
derived endothelial progenitor cells to form a primitive
vasculature. The structure and molecular interactions of
arteriogenesis differ from those of angiogenesis and vascu-
logenesis.
Contrary to conventional paradigms,12 angiogenesis
and vasculogenesis by themselves cannot replace the con-
ductance capacity of collateral arteries in the absence of
arteriogenesis.11,13 According to the results of clinical
trials, the question has been raised about whether the
angiogenesis/vasculogenesis induced by single angiogenic
growth factors can induce functional collateral arteries.14,15
A high local concentration of angiogenic growth factors
increases the risk of atherosclerosis16-18 and tumor angio-
genesis.19 Therefore, an attempt to stimulate the develop-
ment of functional collateral arteries through the process of
arteriogenesis represents an evolution toward a new thera-
peutic strategy for patients with severe ischemia due to
atherosclerotic vascular disease.The primary aim of this study was to test the hypothesis
that NP-mediated delivery of pitavastatin to endothelial
cells can be a realistic strategy for promoting functional
collateral arteries and for improving exercise-induced isch-
emia in a rabbit model of chronic hind limb ischemia.
MATERIALS AND METHODS
The study protocol was reviewed and approved by the
Committee on Ethics in Animal Experiments, KyushuUni-
versity Faculty of Medicine. The experiments were con-
ducted according to the Guidelines of the American Phys-
iological Society.
Preparation of NP. Anionic poly(lactic-co-glycolic
acid) (PLGA) NP incorporated with fluorescein-isothiocyanate
(FITC), pitavastatin, or vatalanib20 (an inhibitor of recep-
tor tyrosine kinase of vascular endothelial cell growth factor
[VEGF] receptors 1-3; a gift of Novartis Pharma) were
prepared by a emulsion solvent diffusion method.10 The
FITC-, pitavastatin-, and vatalanib-incorporated NP con-
tained (w/v) 5% FITC, 6.3% pitavastatin, and 6.1% vata-
lanib, respectively. The diameter of PLGA NP was 196 
29 nm. Additional details are provided in the Appendix
(online only).
Angiogenesis activity of human endothelial cells.
Angiogenesis of human endothelial cells (HECs) was tested
by 2-dimensional Matrigel assay, as previously described.10
Additional details are provided in the Appendix (online
only).
Rabbit model of chronic hind limb ischemia and
treatments. Male Japanese White rabbits were used. To
induce chronic hind limb ischemia, the left femoral artery
was completely excised from its proximal origin at the
branchpoint of the external iliac artery to the bifurcation of
the saphenous and popliteal arteries.21,22 For intramuscular
injection, drugs incorporated with or without NP were
suspended in 5 mL of phosphate-buffered saline (PBS) and
injected into 10 different sites in the left medial thigh
muscles with a 27-gauge needle 7 days after femoral artery
excision (Appendix Fig I, online only). To define the
dose-response relationship of the proarteriogenic effects of
pitavastatin-NP, animals were randomly divided into a PBS
group and three other treatment groups that received an
intramuscular injection of pitavastatin-NP containing the
three different doses of pitavastatin (0.05, 0.15, and 0.5
mg/kg).
In another set of experiments, animals were randomly
distributed in groups receiving intramuscular injections of
PBS, pitavastatin (0.5 mg/kg), FITC-NP, or pitavastatin
(0.5 mg/kg)-NP. The effect of vatalanib-NP on arterio-
genesis induced by pitavastatin-NP was also examined in
another set of animals treated intramuscularly with vatalanib-
NP or with vatalanib-NP and pitavastatin-NP. Additional
details are provided in the Appendix (on-line only).
Effects of pitavastatin-NP on collateral arterial
development 28 days after treatment
Internal iliac angiography. A 4Fr end-hole infusion
catheter was introduced into the right common carotid
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level of the interspaces between the seventh lumbar and the
first sacral vertebrae. After an intra-arterial injection of
nitroglycerin (0.25 mg), 5 mL of contrast medium was
injected at a rate of 1 mL/s. The 3-second angiogram was
used for analysis of the angiographic score. A composite of
5-mm2 grids was placed over the angiogram. The total
number of grids that were crossed by visible arteries was
divided by the total number of grids in the area of the
medial thigh, as previously described.21,22
Capillary and arteriolar density. Histologic evaluation
was performed for 5-m frozen sections or 5-m paraffin-
embedded sections of the adductor skeletal muscles of the isch-
emic limb. CD31 (Dako, Tokyo, Japan) capillary endothelial
cellswere counted.Arterioleswere determinedby immunostain-
ingwith-smoothmuscle actin (-SMA;Dako) andanti-mouse
immunoglobulin G secondary antibody (Alexa 546; Molecular
Probes, Invitrogen, Carlsbad, Calif), and vessels surrounded by
smooth muscle cells were counted. Nuclei were counterstained
with4=,6-diamidino-2-phenylindole (VectorShield,VectorLab-
oratories, Burlingame, Calif). Capillary and arteriolar density
were calculated as capillaries/mm2 and arterioloes/mm2 aver-
aged from five randomly selected fields.21,22 To ensure that the
density was not overestimated or underestimated as a conse-
quence of myocyte atrophy or edema, the capillary/muscle and
arteriolar/muscle fiber ratios were also evaluated.
Tissue oximetry. Tissue oxygen content was mea-
sured by fluorescence quenching technique using an
OxyLab PO2 monitor (Oxford Optronix Ltd, Oxfordshire,
UK) fiberoptic probe mounted to a micromanipulator, as
previously described.23 Ischemic limb was exposed on an
anesthetized animal, and a 18-gauge needle was used to
insert the fiberoptic probe to the adductor skeletal muscles
of the ischemic limb at a 90° angle to contact the adductor
Fig 1. Effects of six statins on angiogenic capacity of hu
of tube formation (tube length inmm per well) in six inde
of variance with the Dunnett multiple comparison test.skeletal muscles. The stable PO2 reading, before a rapid riseto at least 60 mm Hg that signaled loss of tissue contact,
was used as the tissue oxygen partial pressure.
Effects of pitavastatin-NP on forced ischemia in-
duced by electrical pulses. The functional status of collat-
eral arterial development was examined 28 days after treatment
with PBS, FITC-NP, pitavastatin only, and pitavastatin-
NP. After anesthesia, 21-gauge catheters were inserted into
the right femoral artery and the left femoral vein for blood
sampling. Two 21-gauge needles were inserted into the left
medial thigh and the left gastrocnemius muscle. The elec-
trode wires were then connected to the needles and plugged
into the stimulator (Electronic Stimulator, Model SEN-7203,
NIHON KOHDEN, Tokyo, Japan). The stimulating volt-
age was set at 5 V for 1 millisecond to cause noticeable
contraction of the left hind limb. The stimulation fre-
quency was 3 Hz, and the left hind limb was electrically
stimulated for 30 minutes. Arterial and venous blood was
sampled to measure the oxygen saturation before stimula-
tion and at 15 and 30 minutes after stimulation.
A mouse model of hind limb ischemia and treatments.
Male wild-type and Flt-1 tyrosine kinase deficient (Flt-1
TK–/–) mice24 were used. After anesthesia, unilateral hind
limb ischemia was induced in the mice as previously de-
scribed.10,25 Additional details are provided in the Appen-
dix (online only).
Statistical analyses. Data are expressed as mean 
standard error of the mean. Statistical analysis was assessed by
one-way or two-way analysis of variance with post hoc test.
Values of P .05 were considered statistically significant.
RESULTS
Effects of statins and pitavastatin-NP on the angio-
genic capacity of HECs in vitro. Treatment with pitavas-
tatin increased angiogenic activity in HECs, whereas other
ndothelial cells in vitro is shown by quantitative analysis
ent experiments. *P .01 vs control by one-way analysisman e
pendstatins had no effect (Fig 1). Treatment with pitavastatin-
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activity of statin-NPwas greater than that of 10 nM pitavas-
tatin alone (Fig 2).
Effects of pitavastatin-NP on angiographically vis-
ible collateral arterial development. Because only a sin-
gle dose of pitavastatin (0.4 mg/kg)-NP was previously
examined in the mouse model,13 the dose-response rela-
tionship of pitavastatin-NP with angiographically visible
collateral arterial development (arteriogenesis) was exam-
ined in the present study. Treatment with pitavastatin (0.5
mg/kg)-NP, but not with those with pitavastatin at 0.05 or
0.15 mg/kg, increased the arteriogenic response, as as-
sessed by the angiographic score (Fig 3, A). Representative
angiograms 28 days after treatment demonstrate corkscrew-
like collateral arterial development only in the pitavastatin-
NP group (Fig 3, B). Treatment with pitavastatin (0.5
mg/kg)-NP significantly increased the angiographic score
(Fig 3, C). In contrast, no treatment effects on the angio-
graphic score were noted in the FITC-NP or pitavastatin-
only groups.
Effects of pitavastatin-NP on histopathologic an-
giogenesis and arteriogenesis. Treatment with pitavasta-
tin (0.5 mg/kg)-NP, but not with FITC-NP or statin only,
significantly increased the capillary density and capillary/
muscle fiber ratio, which are indices of angiogenesis (Fig 4,
A). The beneficial effects of pitavastatin-NP were not asso-
ciated with significant changes in serum biochemical mark-
ers (Table). Treatment with pitavastatin-NP also signifi-
cantly increased the -SMA arteriolar density and arteriole/
muscle fiber ratio, which are indices of arteriogenesis (Fig
4, B), indicating that pitavastatin-NP treatment induced
angiogenesis and arteriogenesis.
Examination of hematoxylin-eosin-stained sections
revealed no abnormal histopathologic findings (inflam-
mation and fibrosis) among the four groups (data not
shown). There was no significant difference in muscle
fiber density among the four groups (PBS groups: 129
8, 145 4/mm2; FITC-NP groups: 130 3 and 129
Fig 2. Effects of pitavastatin and pitavastatin nanoparticles (NP)
are shown on the angiogenic capacity of human endothelial cells in
vitro by quantitative analysis of tube formation (tube length per
well) of six independent experiments. *P  .01 vs control by
two-way analysis of variance with the Dunnett multiple compari-
son test.6/mm2).Effects of pitavastatin-NP on tissue oxygen saturation.
The tissue oxygen pressure in adductor skeletal muscles of
the ischemic limb was measured 28 days after treatment.
Treatment with pitavastatin (0.5 mg/kg)-NP significantly
increased tissue oxygen pressure compared with the other
groups (Appendix Fig II, online only).
Endothelial cell-selective delivery of NP. The cellu-
lar distribution of FITC was examined 3, 7, and 28 days
after the intramuscular injection of FITC-NP or FITC
only. On day 3 after injection, strong FITC signals were
detected in FITC-NP–injected ischemic muscle (Fig 5, A),
whereas no FITC signals were observed in control nonisch-
emic muscle (Fig 5, A) or in ischemic muscle injected with
FITC only (data not shown). The FITC signals were local-
ized predominantly to the capillaries and arterioles. Weak
FITC signals were also detected in myocytes at day 3t. On
Fig 3. Effects of pitavastatin nanoparticles (NP) on angiographi-
cally visible collateral arterial development are shown 28 days after
treatment. A, Effects of pitavastatin-NP containing 0.05, 0.15, or
0.5 mg/kg pitavastatin on the angiographic score (n 3 each). B,
Representative angiograms are shown of the phosphate buffered saline
(PBS), pitavastatin-only, fluorescein isothiocyanate (FITC)-NP, and
pitavastatin-NP groups at 28 days after treatment. Corkscrew-like col-
lateral arteries were observed only in the pitavastatin-NP group.C,
Summary of the angiographic scores obtained for the four groups
in panel B (n  6 each).day 7 and 28, FITC signals remained localized predomi-
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orescent staining revealed that FITC signals localized
mainly to CD31 endothelial cells in FITC-NP–injected
ischemic muscle 28 days after ischemia (Fig 5, B). In
contrast, no FITC signals were observed in skeletal muscle
myocytes on day 7 and 28 or in contralateral nonischemic
hind limbs or remote organs (liver, spleen, kidney, and
heart) at any time point (data not shown).
Effects of pitavastatin-NP on exercise-induced isch-
emia induced by electrical stimulation. To assess the
functional efficacy of pitavastatin-NP on collateral arterial
development, the effects of pitavastatin-NP on exercise-
induced ischemia by electrical stimulation were examined.
In the control PBS group, venous oxygen saturation in
ischemic muscle decreased, and thus the difference in arte-
riovenous oxygen saturation increased after 15 and 30
minutes of electrical stimulation (Fig 6, A), suggesting the
occurrence of exercise-induced ischemia. Treatment with
pitavastatin-NP, but not with FITC-NP or pitavastatin
only, abrogated the increase in arteriovenous oxygen dif-
Fig 4. Effects of pitavastatin nanoparticles (NP) on angiogenesis
and arteriogenesis are shown 28 days after treatment. A, CD-31
capillary density and capillary/muscle fiber ratio (indices of angio-
genesis) is shown in ischemic muscles (n  6 each). B, -Smooth
muscle actin (-SMA)-positive arteriolar density and arteriole/
muscle fiber ratio is shown in ischemic muscles (indices of arterio-
genesis; n 8 each). FITC,Fluorescein isothiocyanate;PBS, phosphate-
buffered saline; SMC, smooth muscle cells.ference in the ischemic limb (Fig 6, B). There were nosignificant differences in systemic blood hemoglobin levels
among the four groups (data not shown).
Effects of vatalanib-NP on angiogenesis and arte-
riogenesis induced by pitavastatin-NP. We recently re-
ported in a murine model that therapeutic neovasculariza-
tion induced by pitavastatin-NP was mediated by increased
eNOS activity and multiple endogenous angiogenic growth
factors, such as VEGF.10,25 Consequently, we examined
VEGF expression in the four groups 28 days after treatment
by immunohistochemistry and found increased VEGF pos-
itivity in CD31 endothelial cells of the capillaries and
arterioles in the pitavastatin-NP group compared with
other groups (Appendix Fig III, online only). Interestingly,
positive VEGF staining was also detected inmyocytes in the
pitavastatin-NP group.
Vatalanib was selected because this molecule inhibits
receptor tyrosine kinases of VEGR receptor types 1-3.
Treatment with vatalanib-NP elicited no effects on angio-
graphically visible collateral arterial development induced
by hind limb ischemia in animals treated with PBS; how-
ever, it abrogated the arteriogenic response induced by
pitavastatin-NP (Fig 7, A and B). In addition, treatment
with vatalanib-NP abrogated histopathologic, angio-
genic (capillary density), and arteriogenic (arteriolar den-
sity) responses induced by pitavastatin-NP (Fig 7, C).
Vatalanib-NP elicited significant effects on histopathologic
arteriogenic (arteriolar density) responses under baseline
conditions (Fig 7, C).
Effects of pitavastatin-NP on angiogenesis and ar-
teriogenesis in flt-1 TK–/– mice transfected with and
without the sFlt-1 gene. To examine the role of VEGF
receptors (flk-1 and flt-1), the effects of pitavastatin-NP on
ischemia-induced neovascularization were examined in
wild-type and flt-1 TK–/– mice (Appendix Fig IV, online
only). Compared with wild-type mice, the therapeutic ef-
fects of pitavastatin-NP decreased but were still observed in
flt-1 TK–/– mice. To further examine the role of flk-1,
sFlt-1 gene transfer was performed into flt-1 TK–/– mice.
The sFlt-1 gene transfer blunted the therapeutic effects of
pitavastatin-NP.
DISCUSSION
The present study demonstrates that NP-mediated en-
dothelial cell-selective delivery of pitavastatin increased the
development of collateral arteries (arteriogenesis) and im-
proved exercise-induced ischemia in a rabbit model of
chronic hind limb ischemia, indicating that this novel cell-
selective delivery system is feasible for therapeutic arterio-
genesis. We selected this rabbit model for translation to
clinical settings in humans because it represents a preclinical
model of arteriogenesis after femoral artery occlusion,26 as
observed in patients with severe peripheral artery disease.
Stimulation of the growth of collateral arteries (arterio-
genesis) is evolving as a new therapeutic option for patients
with atherosclerotic occlusive vascular disease, even though
induction of additional angiogenesis or vasculogenesis is
beneficial.11,13 We assumed that the vascular endothelium
would be an appropriate cellular target for the development
urea n
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endothelium plays a central role in the mechanism of arte-
riogenesis by expressing multiple growth factors and by
recruiting monocytes and smooth muscle cells. We found
that FITC signals were localized mainly to the vascular
endothelium for up to 4 weeks after the injection of
FITC-NP into ischemic skeletal muscles of rabbits in vivo,
indicating that this NP-mediated delivery system may be
useful as an innovative strategy for a therapy targeting
endothelial cells. We recently reported that after cellular
delivery of NP by endocytosis into endothelial cells, the
PLGANP escapes from the endosomal compartment to the
cytoplasmic compartment and is retained in the cytoplasm,
where release of the encapsulated drug occurs slowly in
conjunction with the hydrolysis of PLGA.10,27-29
Daily administration of statins at high doses has been
reported to augment arteriogenesis in normocholester-
olemic rabbits.6 These pleiotropic effects of statins are
mediated through reduced levels of cholesterol biosynthe-
sis pathway intermediates that serve as lipid attachments for
post-translational modification (isoprenylation) of pro-
teins, including Rho and Rac. Pitavastatin was selected as
the NP compound because (1) pitavastatin elicited the
most potent effects on the angiogenic activity of HECs in
vitro compared with other statins, and (2) NP-mediated
Table. Serum biochemical profiles
Variablea PBS
CPK (U/L)
Day 7 345  30
Day 14 279  8
Day 21 242  16
Day 28 275  60
AST (IU/L)
Day 7 10  1
Day 14 7  0.3
Day 21 15  1
Day 28 31  11
ALT (IU/L)
Day 7 36  9
Day 14 26  1
Day 21 38  7
Day 28 42  8
BUN (mg/dl)
Day 7 24  0.2 1
Day 14 23  1 1
Day 21 19  1
Day 28 26  1
Creatinine (mg/dL)
Day 7 0.66  0.01 0
Day 14 0.70  0.04 0
Day 21 0.95  0.02 0
Day 28 0.85  0.08 0
Total cholesterol (mg/dL)
Day 7 31  10
Day 14 26  8
Day 21 29  10
Day 28 18  3
ALT, Alanine aminotransferase; AST, aspartate transaminase; BUN, blood
aData are mean  standard error of the mean (n  3 each).intracellular delivery of pitavastatin showed greater angio-genic activity of HECs compared with pitavastatin alone
(Figs 1 and 2).
We also found in an in vivo rabbit model that (1) a
single intramuscular injection of pitavastatin-NP increased
the angiographic score in a dose-dependent manner, (2)
pitavastatin (0.5 mg/kg) -NP significantly increased arte-
riogenesis and tissue oxygen pressure (tissue perfusion),
and (3) the treatment of pitavastatin-NP increased immu-
noreactive VEGF expression selectively in vascular endo-
thelial cells in the ischemic limb. Therefore, it is likely that
that after NP-mediated endothelial delivery, pitavastatin is
slowly released from theNP into the cytoplasm, resulting in
significant therapeutic effects. Sata et al8 reported that
systemic daily administration of pitavastatin (1 mg/kg/day 
49 days  49 mg/kg) has significant therapeutic effects in
mice with hind limb ischemia. In our previous study, we
reported the efficacy of pitavastatin (0.4 mg/kg)-NP in a
murine model.10 Therefore, at an approximately 100-fold
lower dose, our NP-mediated delivery system is as effective
as the cumulative systemic dose.
In clinical trials that examined the effects of a single
vascular growth factor on peripheral and coronary artery
disease, clinical end points such as increased exercise toler-
ance were negative or disappointing, although increased
vascularity was noted.14,15 It has been reported that limb
-NP Pitavastatin only Pitavastatin-NP
270 445  98 385  44
38 459  118 296  18
58 396  72 252  12
15 275  33 259  31
3 16  2 10  1
3 19  6 8  3
2 22  7 19  4
6 18  2 20  2
10 38  5 29  11
6 37  7 33  9
5 37  8 43  11
10 35  11 53  19
0.2 18  1.5 24  2
2 24  2 25  1
4 20  2 19  0.4
0.3 17  0.4 29  2
0.07 0.89  0.01 0.80  0.11
0.09 0.87  0.08 0.73  0.05
0.06 0.95  0.01 1.03  0.02
0.06 0.86  0.03 0.92  0.03
1 19  5 46  5
3 19  1 31  4
1 18  3 32  6
2 21  1 17  2
itrogen; CPK, creatinine phosphokinase.FITC
766 
486 
535 
229 
19 
19 
20 
29 
36 
34 
33 
41 
7.3 
9.6 
18 
17 
.82 
.81 
.80 
.91 
31 
24 
18 
18 hemodynamics, such as ankle-brachial index or muscle
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ity (claudication time or walking distance) in patients with
peripheral arterial disease.30 Therefore, assessment of the
functional capacity of neovessels is needed in preclinical
studies in animals. In other words, the improved functional
capacity of collateral arteries must be a clinically important
therapeutic goal in preclinical studies; however, few previ-
ous preclinical studies have addressed this point.
In the present study, we demonstrate that the arterio-
venous oxygen difference in the ischemic hind limb in-
creased in response to exercise in the PBS group, suggesting
the development of exercised-induced ischemia. Treatment
with pitavastatin-NP, but not with FITC-NP or pitavasta-
tin only, prevented the development of exercise-induced
ischemia. These data suggest that therapeutic arteriogen-
esis induced by pitavastatin-NP is associated with improved
Fig 5. Cellular distribution of nanoparticles is shown in ischemic
muscles. A, Fluorescent photomicrographs show cross sections of
control nonischemic muscle and ischemic muscles at 3, 7, and 28
days after fluorescein isothiocyanate (FITC) nanoparticle (NP)
injection. Nuclei were counterstained with 4=,6-diamidino-2-
phenylindole (blue). Fluorescence microscopic settings (exposure,
filter, excitation light intensity, etc.) were the same for all images.
Scale bar  100 m. B, Photomicrographs of cross sections of
ischemic muscle 28 days after FITC-NP injection stained immu-
nohistochemically with the endothelial marker CD31 (red). Most
FITC signals colocalized with the vascular endothelium (arrows).
Scale bars  20 m.functional capacity.We previously reported that the beneficial therapeutic
effects induced by pitavastatin-NP are mediated by in-
creased eNOS activity and multiple endogenous angio-
genic growth factors in a murine model.10 Recent reports
by others have shown that mice lacking VEGF receptor 1 or
placenta growth factor (a specific agonist of VEGR receptor
1), but not those lacking VEGF receptor 2, display im-
paired development of ischemia-induced angiogenesis and
arteriogenesis.31-33 However, roles of endogenous angio-
genic growth factors in the mechanism of therapeutic ef-
fects of pitavastatin-NP have not been addressed.
In the present study, vatalanib-NP abrogated arterio-
genic and angiogenic responses to pitavastatin-NP in rab-
bits. Furthermore, experiments with flt-1 TK–/– mice
transfected with or without the sFlt-1 gene showed partial
contribution of both flt-1 and flk-1 to therapeutic angio-
genic effects of pitavastatin-NP. These findings suggest that
Fig 6. Effects are shown of pitavastatin nanoparticles (NP) on
exercise-induced ischemia induced by electrical stimulation. A,
Oxygen saturation in the femoral artery and vein in ischemic
muscle is shown before and 15 and 30 minutes after muscular
exercise by electrical stimulation in the phosphate-buffered saline
(PBS) group (n 6 each). B, The difference in arterial and venous
oxygen saturation after 30 minutes of electrical pulse is shown in
the four groups (n  6 each). FITC, Fluorescein isothiocyanate.pitavastatin-NP produces an integrative system to form
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 2 Oda et al 419functionally mature collaterals by controlled expression of
endogenous VEGF and its receptor signals.
There are several limitations to the present study. First,
only a single intramuscular injection of pitavastatin-NP was
examined. In clinical settings, repetitive administration of
an optimal dose may produce greater therapeutic effects.
Second, we did not examine the contribution of bone
marrow-derived progenitor cells because appropriate anti-
bodies for detecting endothelial or smooth muscle progen-
itor cells are not available in rabbits. Further studies are
needed to examine whether therapeutic effects afforded by
pitavastatin-NP are associated with an increase in circulat-
ing endothelial progenitor cells.
CONCLUSIONS
This nanotechnology platform for vascular endothelial
cell-selective delivery of pitavastatin is a promising strategy
for the treatment of patients with severe organ ischemia and
represents a significant advance in therapeutic arteriogen-
esis over current approaches. The nanotechnology platform
may be further developed as a more effective and safer
Fig 7. Effects of vatalanib nanoparticles (NP) are shown on an-
giogenesis and arteriogenesis induced by pitavastatin-NP. A, Rep-
resentative angiograms show vatalanib-NP only and vatalanib-NP
plus pitavastatin-NP groups 28 days after treatment. B, Summary
of the angiographic scores obtained for the four groups (n  3
each). C, Effects of vatalanib-NP are shown on histopathologic
angiographic (capillary density) and arteriogenic (SMC-positive
arteriolar density) responses induced by pitavastatin-NP.approach for therapeutic neovascularization.AUTHOR CONTRIBUTIONS
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